{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:00:00Z","timestamp":1768258800864,"version":"3.49.0"},"reference-count":58,"publisher":"Scientific Scholar","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Paediatric chronic myeloid leukaemia (CML) has biological and clinical differences from adult CML. Management of paediatric CML presents unique challenges in growing children, and there are no specific guidelines for paediatric CML. This review focusses on the clinical characteristics, diagnostic issues and management of paediatric CML. Major studies that provide the basis of managing paediatric CML are summerized here. Studies conducted on adult CML patients were used to guide the management of places where studies were lacking in paediatric CML. Recently, dasatinib and nilotinib have been approved for treatment of paediatric CML, and their role has been discussed in the current management perspective. Allogeneic transplant, fertility and vaccination in paediatric CML, have also been discussed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_331_19","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T07:29:56Z","timestamp":1566372596000},"page":"600-609","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Paediatric chronic myeloid leukaemia"],"prefix":"10.25259","volume":"149","author":[{"given":"Deepam","family":"Pushpam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"R1-6-20241212","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/ped.12876","article-title":"Optimal management for pediatric chronic myeloid leukemia: CML in childhood","volume":"58","author":"Tanizawa","year":"2016","journal-title":"Pediatr Int"},{"key":"R2-6-20241212","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-6-20241212","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","article-title":"Characteristics of accelerated disease in chronic myelogenous leukemia","volume":"61","author":"Kantarjian","year":"1988","journal-title":"Cancer"},{"key":"R4-6-20241212","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2016.08.011","article-title":"Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America","volume":"67","author":"Karalexi","year":"2016","journal-title":"Eur J Cancer"},{"key":"R6-6-20241212","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0971-5851.123712","article-title":"Report of chronic myeloid leukemia in chronic phase from All India Institute of Medical Sciences, 1990-2010","volume":"34","author":"Mishra","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"R8-6-20241212","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/gcc.21989","article-title":"Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia","volume":"51","author":"Krumbholz","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"R9-6-20241212","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: Clinical findings, management, and unanswered questions","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"R10-6-20241212","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"R11-6-20241212","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"key":"R12-6-20241212","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"R13-6-20241212","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood.V120.21.3741.3741","article-title":"The international registry for chronic myeloid leukemia (CML) in children and adolescents (I-CML-Ped-Study): Objectives and preliminary results","volume":"120","author":"Millot","year":"2012","journal-title":"Blood"},{"key":"R14-6-20241212","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12185-012-1010-4","article-title":"Patient characteristics and treatment patterns in chronic myeloid leukemia: Evidence from a multi-country retrospective medical record chart review study","volume":"95","author":"Mitra","year":"2012","journal-title":"Int J Hematol"},{"key":"R15-6-20241212","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4103\/ijmpo.ijmpo_104_16","article-title":"Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric chronic myeloid leukemia chronic phase on frontline imatinib","volume":"38","author":"Ganta","year":"2017","journal-title":"Indian J Med Paediatr Oncol"},{"key":"R18-6-20241212","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2011-10-380774","article-title":"How I treat childhood CML","volume":"119","author":"Andolina","year":"2012","journal-title":"Blood"},{"key":"R19-6-20241212","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/ijmpo.ijmpo_62_17","article-title":"The biology of chronic myelogenous leukemia in childhood and young adolescents: An Indian perspective","volume":"39","author":"Chandra","year":"2018","journal-title":"Indian J Med Paediatr Oncol"},{"key":"R20-6-20241212","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s12098-015-2007-9","article-title":"Impact of imatinib adherence on the cytogenetic response in pediatric chronic myeloid leukemia \u2013 Chronic phase","volume":"83","author":"Ganta","year":"2016","journal-title":"Indian J Pediatr"},{"key":"R21-6-20241212","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R22-6-20241212","first-page":"795","article-title":"Lineage involvement by BCR\/ABL in Ph+ lymphoblastic leukemias: Chronic myelogenous leukemia presenting in lymphoid blast vs.Ph+ acute lymphoblastic leukemia","volume":"10","author":"Anastasi","year":"1996","journal-title":"Leukemia"},{"key":"R23-6-20241212","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1600-0609.1977.tb01474.x","article-title":"The peripheral blood in chronic granulocytic leukaemia. Study of 50 untreated Philadelphia-positive cases","volume":"18","author":"Spiers","year":"1977","journal-title":"Scand J Haematol"},{"key":"R24-6-20241212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x","article-title":"Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period","volume":"96","author":"Savage","year":"1997","journal-title":"Br J Haematol"},{"key":"R25-6-20241212","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1309\/AJCPUN89CXERVOVH","article-title":"Chronic myelogenous leukemia, BCR-ABL1+","volume":"132","author":"Vardiman","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"R26-6-20241212","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/10428190009148850","article-title":"Bone marrow features and clinical findings in chronic myeloid leukemia \u2013 A comparative, multicenter, immunohistological and morphometric study on 614 patients","volume":"36","author":"Thiele","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"R27-6-20241212","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"R28-6-20241212","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2016.10.005","article-title":"Management of CML-blast crisis","volume":"29","author":"Hehlmann","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"key":"R29-6-20241212","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","article-title":"Managing children with chronic myeloid leukaemia (CML): Recommendations for the management of CML in children and young people up to the age of 18 years","volume":"167","author":"de la Fuente","year":"2014","journal-title":"Br J Haematol"},{"key":"R30-6-20241212","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"key":"R31-6-20241212","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3109\/10428194.2012.694076","article-title":"Chronic myeloid leukemia in children and adolescents: Results of treatment with imatinib mesylate","volume":"53","author":"Lakshmaiah","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R32-6-20241212","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"R33-6-20241212","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjh.13453","article-title":"Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: The Italian experience","volume":"170","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"key":"R34-6-20241212","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R35-6-20241212","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2018.1398644","article-title":"Pharmacology and pharmacokinetics of imatinib in pediatric patients","volume":"11","author":"Suttorp","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R36-6-20241212","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"key":"R37-6-20241212","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R38-6-20241212","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/pbc.26028","article-title":"Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia","volume":"63","author":"Samis","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R39-6-20241212","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"},{"key":"R40-6-20241212","doi-asserted-by":"crossref","first-page":"CR721","DOI":"10.12659\/MSM.883599","article-title":"Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment","volume":"18","author":"Jaeger","year":"2012","journal-title":"Med Sci Monit"},{"key":"R41-6-20241212","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid"},{"key":"R42-6-20241212","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: Results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J Clin Oncol"},{"key":"R43-6-20241212","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"R45-6-20241212","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European leukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"R46-6-20241212","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"R47-6-20241212","doi-asserted-by":"crossref","first-page":"e27368","DOI":"10.1002\/pbc.27368","article-title":"Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia\/Lymphoma Study Group","volume":"65","author":"Kurosawa","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R48-6-20241212","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","article-title":"Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis","volume":"77","author":"Campiotti","year":"2017","journal-title":"Eur J Cancer"},{"key":"R49-6-20241212","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: Who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R50-6-20241212","doi-asserted-by":"crossref","first-page":"Iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"R51-6-20241212","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.24521","article-title":"Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase","volume":"61","author":"Millot","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R52-6-20241212","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.13103","article-title":"Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia","volume":"168","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"key":"R54-6-20241212","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clml.2013.08.008","article-title":"Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase","volume":"14","author":"Ohanian","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R55-6-20241212","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"R56-6-20241212","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"key":"R57-6-20241212","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MPH.0000000000000636","article-title":"Outcomes following bone marrow transplantation in children with accelerated phase or blast crisis chronic myelogenous leukemia in the era of tyrosine kinase inhibitors","volume":"38","author":"Shulman","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"R58-6-20241212","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2009.09.022","article-title":"Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: The Japan Marrow Donor Program","volume":"16","author":"Muramatsu","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R59-6-20241212","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","article-title":"Stem cell transplantation for chronic myeloid leukemia in children","volume":"102","author":"Cwynarski","year":"2003","journal-title":"Blood"},{"key":"R60-6-20241212","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","article-title":"Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: Results from the prospective trial CML-paed I","volume":"221","author":"Suttorp","year":"2009","journal-title":"Klin Padiatr"},{"key":"R61-6-20241212","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11523-017-0521-6","article-title":"Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase","volume":"12","author":"Chang","year":"2017","journal-title":"Target Oncol"},{"key":"R62-6-20241212","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","article-title":"Management of pregnant chronic myeloid leukemia patients","volume":"9","author":"Abruzzese","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"R63-6-20241212","doi-asserted-by":"crossref","first-page":"E2014028","DOI":"10.4084\/mjhid.2014.028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Abruzzese","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R64-6-20241212","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s13312-014-0504-y","article-title":"Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years \u2013 India, 2014 and updates on immunization","volume":"51","author":"Vashishtha","year":"2014","journal-title":"Indian Pediatr"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02223309-201949050-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:01:43Z","timestamp":1751497303000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/paediatric-chronic-myeloid-leukaemia-is-it-really-a-different-disease\/"}},"subtitle":["Is it really a different disease?"],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_331_19","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}